Company Filing History:
1 out of 576 
1 out of 61 
1 out of 1 Years Active: 2011-2014
Title: Helmut R Maecke: Innovator in Somatostatin Research
Introduction
Helmut R Maecke is a notable inventor recognized for his contributions to the field of somatostatin research. His work primarily focuses on developing receptor antagonists that have significant implications for diagnosing and treating various diseases. Despite having no patents registered under his name, his research has led to innovative advancements in medical science.
Latest Patents
Maecke's latest patents include the development of somatostatin receptor 2 antagonists. These patents describe somatostatin analogs that act as receptor antagonists, particularly selective for SSTR2. The compounds developed are useful in diagnosing and treating both neoplastic and non-neoplastic mammalian diseases. Another significant patent involves receptor-selective somatostatin antagonists that bind with high affinity to the cloned human receptor SSTR2 without activating it. This selectivity helps avoid potential side effects associated with other receptors, making these antagonists valuable for therapeutic applications.
Career Highlights
Throughout his career, Helmut R Maecke has worked with prestigious institutions such as the Salk Institute for Biological Studies and the University of Bern. His research has contributed to a deeper understanding of somatostatin's role in physiological processes and its potential therapeutic applications.
Collaborations
Maecke has collaborated with various professionals in his field, including Judit Erchegyi. These collaborations have enhanced the scope and impact of his research, leading to significant advancements in somatostatin-related therapies.
Conclusion
Helmut R Maecke's innovative work in somatostatin receptor antagonists showcases his dedication to advancing medical science. His contributions, although not reflected in patents, have the potential to influence future therapeutic strategies significantly.